Merakris Advances Potentially Pivotal MTX-001 Phase 2/3 Strategy Following FDA Pre-IND Meeting
Financial Post ·
FDA indicates proposed double-blind Phase 2/3 design could be considered adequate and well controlled as Merakris prepares its first commercial-pilot GMP drug lot for a potentially pivotal trial. RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) — Merakris Therapeutics, Inc., a clinical-stage biotechnology company developing regenerative biologic medicines, today announced receipt of the U.S. […]
FDA indicates proposed double-blind Phase 2/3 design could be considered adequate and well controlled as Merakris prepares its first commercial-pilot GMP drug lot for a potentially pivotal trial. Read More